Note 2.500% 3/1 · CUSIP 10806XAB8 · who reports it, how much, and how much it matters to them
7 of the 720 hedge fund managers we track reported shares of Bridgebio Pharma Inc on Form 13F for 30 June 2026. Between them they reported USD 427m. The largest position belongs to Wolverine Asset Management, at USD 136m. The manager with the most riding on it is 683 Capital Management, where it is 1.9% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Wolverine Asset Management1 fund on PPLI.com | USD 136m | 1.2% |
| 2 | Capstone Investment Advisors25 funds on PPLI.com | USD 124m | 0.2% |
| 3 | Moore Capital Management7 funds on PPLI.com | USD 57m | 0.8% |
| 4 | Graham Capital Management18 funds on PPLI.com | USD 40m | 0.7% |
| 5 | 683 Capital Management2 funds on PPLI.com | USD 39m | 1.9% |
| 6 | Millennium Management6 funds on PPLI.com | USD 31m | 0.0% |
| 7 | Gamco Asset Management1 fund on PPLI.com | USD 536,000 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | 683 Capital Management | USD 39m | 1.9% |
| 2 | Wolverine Asset Management | USD 136m | 1.2% |
| 3 | Moore Capital Management | USD 57m | 0.8% |
| 4 | Graham Capital Management | USD 40m | 0.7% |
| 5 | Capstone Investment Advisors | USD 124m | 0.2% |
| 6 | Millennium Management | USD 31m | 0.0% |
| 7 | Gamco Asset Management | USD 536,000 | 0.0% |
7 of the 720 hedge fund managers PPLI.com tracks reported Bridgebio Pharma Inc shares on Form 13F for 30 June 2026. The largest reported positions were held by Wolverine Asset Management (USD 136m), Capstone Investment Advisors (USD 124m), Moore Capital Management (USD 57m), Graham Capital Management (USD 40m) and 683 Capital Management (USD 39m).
7 managers in our coverage reported it, and between them they run 60 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
683 Capital Management, where the position was 1.9% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Bridgebio Pharma Inc or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.